Target Information

Beta Drugs Limited, commonly referred to as Beta Drugs, is a prominent oncology-focused formulations company listed on the SME Exchange in India. The company has successfully raised INR 117 crore (approximately USD 14 million) through a preferential allotment to HealthQuad Fund II and other investors, resulting in a minority stake acquisition. Notably, Beta Drugs specializes in a comprehensive range of oncology products spanning chemotherapy, targeted therapies, hormonal therapies, and supportive care products. It made a significant mark in the industry by being the first Indian company to introduce oncology drugs in suspension form.

As one of the select vertically integrated manufacturers in India, Beta Drugs has solidified its position within the domestic market and expanded its operations across 46 countries. The company holds various accreditations from reputable regulatory agencies, including ANVISA Brazil, INVIMA, PICS, and EAEU. Furthermore, it was recognized with the 2024 Forbes